drugset / Trial / NCT05465343
Furmonertinib in EGFR-Mutant NSCLC With Brain Metastases (iFORCE)
NaSingle-groupOpen-labelTreatment
Summary
This study is a single-arm, open-label, prospective phase II trial. The aim of this phase II study is to evaluate the efficacy and safety of Furmonertinib in patients with EGFR mutation (including 19del or 21L858R or T790M) in advanced NSCLC with brain metastases.
Timeline
- Start
- 2022-07-11
- Primary completion
- 2025-12-12
- Completion
- 2025-12-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Firmonertinib | Small molecule | 160 mg | Oral |